Biotech shares plunge after lung cancer drug's failure

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

Evotec, Vistagen lay off staff; Immutep shares collapse on study failure

Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.

Biotech shares plunge after lung cancer drug's failure

An ASX biotech formerly worth over $500 million has lost most of its value after its drug failed to treat lung cancer effectively.

Regal-backed Immutep dives 90pc after it abandons cancer drug trial

More than $500 million was wiped from the company’s market capitalisation in a blow to major investors including the Phil King-run fund management giant.

Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination

Immutep will now assess the available data to decide the next steps for progressing efti's development in oncology.The post Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination appeared first on Clinical Trials Arena.

A LAG-3 pioneer fails in Phase 3, pouring more cold water on a once-hot cancer target

Immutep said its lead LAG-3 drug candidate flunked an interim futility analysis for a Phase 3 lung cancer study, triggering plans to wind down the trial as its stock takes a hit.